MedTrace Logo

CBT as an Adjunct to SRIs in the Treatment of BDD

NCT00211809 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-03-09

Study results available
· View outcomes & findings →

Summary

The research project is a controlled pilot study of the efficacy of cognitive-behavioral therapy (CBT) as an adjunct to serotonin reuptake inhibitor (SRI) pharmacotherapy in body dysmorphic disorder (BDD). This study assesses the efficacy of CBT in comparison to relaxation and stress management training (RSMT), an active control treatment

Conditions

  • Body Dysmorphic Disorder

Interventions

BEHAVIORAL

Cognitive Behavioral Therapy

standard psychiatric evaluation

DRUG

Venlafaxine

start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.

Sponsors & Collaborators

Principal Investigators

  • Eric Hollander, MD · Icahn School of Medicine at Mount Sinai

  • Andrea Allen, PhD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00211809 on ClinicalTrials.gov